Position in ANIK
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$206,190
+$48,058 QoQ
Shares Held
14,220
-13.6% QoQ
Ownership
0.107%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ANIK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Cetera Investment Advisers holds $48,125,230 across 32 Drug Manufacturers - Specialty & Generic names. ANIK ranks #26 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
80,566 | $9,523,706 | |
| 2 | VTRS |
Viatris Inc
|
385,999 | $5,214,846 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
8,648 | $5,128,091 | |
| 4 | TAK |
Takeda Pharmaceutical Co Ltd
|
224,015 | $4,148,757 | |
| 5 | ELAN |
Elanco Animal Health Inc
|
121,502 | $2,907,542 | |
| 6 | NBIX |
Neurocrine Biosciences Inc
|
20,245 | $2,667,076 | |
| 7 | TEVA |
Teva Pharmaceutical Industries Ltd
|
87,216 | $2,626,945 | |
| 8 | HLN |
Haleon plc
|
247,741 | $2,479,887 |
All Filings in ANIK
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $206,190 | 14,220 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $158,132 | 16,455 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $197,964 | 21,060 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $206,405 | 19,509 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $151,833 | 10,102 | Shares | Sole | 2025-05-06 | |
| No filing history on record for this holder in this stock. | ||||||